Kelly Lawrence W & Associates Inc. CA cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 56.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,605 shares of the biopharmaceutical company’s stock after selling 38,150 shares during the quarter. Kelly Lawrence W & Associates Inc. CA’s holdings in Gilead Sciences were worth $2,096,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. lifted its position in Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its position in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. lifted its position in Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. American Beacon Advisors Inc. acquired a new position in Gilead Sciences during the first quarter valued at $143,000. Finally, Crestwood Advisors Group LLC lifted its position in Gilead Sciences by 11.4% during the second quarter. Crestwood Advisors Group LLC now owns 2,730 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 279 shares during the period. 73.98% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 81.98 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The stock has a 50 day moving average of $81.25 and a 200 day moving average of $71.82. The stock has a market cap of $107.06 billion, a PE ratio of 8.90 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.08 earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is presently 22.58%.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP James R. Meyers sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the completion of the transaction, the executive vice president now directly owns 62,715 shares of the company’s stock, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last three months, insiders sold 486,819 shares of company stock valued at $39,298,919. Company insiders own 1.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Shares Sold by Kelly Lawrence W & Associates Inc. CA” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/10/gilead-sciences-inc-gild-shares-sold-by-kelly-lawrence-w-associates-inc-ca.html.

GILD has been the subject of a number of research reports. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. Morgan Stanley restated an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price for the company. Robert W. Baird restated an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, August 29th. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.66.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.